2095128-20-2
Chemical Structure
Bocidelpar
Synonym(s): ASP0367; MA-0211
- CAS No.: 2095128-20-2
- Formula:C25H27F3N2O3
- Molecular Weight:460.49
IUPAC Name: (R)-3-methyl-6-(2-((5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-1-yl)methyl)phenoxy)hexanoic acid
InChIKey: FMOPHFSPINWSOV-QGZVFWFLSA-N
SMILES: O=C(O)C[C@H](C)CCCOC1=CC=CC=C1CN2C(C)=CN=C2C3=CC=C(C(F)(F)F)C=C3
Biological Activity: Bocidelpar (ASP0367; MA-0211) is a selective, orally active PPARδ modulator. Bocidelpar activates the PPARδ downstream signaling pathway, upregulates the expression of target genes such as ABCA1 and ACAA2. Bocidelpar then promotes fatty acid oxidation (FAO) and mitochondrial biogenesis, and improves mitochondrial dysfunction. Bocidelpar can improve mitochondrial biogenesis and function in muscle cells. Bocidelpar is mainly used in the study of mitochondrial dysfunction diseases such as primary mitochondrial myopathy (PMM) and Duchenne muscular dystrophy (DMD)[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Bocidelpar | 98.08% | Bocidelpar (ASP0367; MA-0211) is a selective, orally active PPARδ modulator. Bocidelpar activates the PPARδ downstream signaling pathway, upregulates the expression of target genes such as ABCA1 and ACAA2. Bocidelpar then promotes fatty acid oxidation (FAO) and mitochondrial biogenesis, and improves mitochondrial dysfunction. Bocidelpar can improve mitochondrial biogenesis and function in muscle cells. Bocidelpar is mainly used in the study of mitochondrial dysfunction diseases such as primary mitochondrial myopathy (PMM) and Duchenne muscular dystrophy (DMD). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Ito M, et al. Single- and multiple-dose safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of ASP0367, or bocidelpar sulfate, a novel modulator of peroxisome proliferator-activated receptor delta in healthy adults: Results from a phase 1 study. Muscle Nerve. 2022 Jan;65(1):110-120. [Content Brief]
- [2]. Diniz Gulden, et al. A Quick Glance at the Therapeutic Approaches for Neuromuscular Disorders. Clues for Differential Diagnosis of Neuromuscular Disorders. Cham: Springer International Publishing, 2023. 329-344.
Keywords
